Incyte Corporation (INCY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $24.51B
Last updated: Nov 17, 2026 at 4:35 PM ET
Incyte Corporation (INCY) Stock Chart
Incyte (INCY) has a latest price of $119.09 on Nov 17, 2026, 10.2% below its 52-week high of $132.60. Its price rose 14.3% over the past 12 months. The month-end price rose 38.4% over the 10 years through Oct 2026, a compound annual rate of 3.3%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $137.41 in Aug 2017 and its lowest $52.05 in Apr 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart INCY with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for INCY.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 7.3%, and over 6 months it rose 24.6%. The month-end price rose 123.2% over the 3 years through Oct 2026, a compound annual rate of 30.7%.
| Period | Change |
|---|---|
| 1 month | +5.2% |
| 3 months | -7.3% |
| 6 months | +24.6% |
| 12 months | +14.3% |
| 12 months, with dividends | +14.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +123.2% | +30.7% |
| 5 years | +79.7% | +12.4% |
| 10 years | +38.4% | +3.3% |
Price by Year
Its best calendar year was 2025, when the price rose 43.0%, and its weakest was 2018, when it fell 32.9%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $120.39 | +21.9% |
| 2025 | $98.77 | +43.0% |
| 2024 | $69.07 | +10.0% |
| 2023 | $62.79 | -21.8% |
| 2022 | $80.32 | +9.4% |
| 2021 | $73.40 | -15.6% |
| 2020 | $86.98 | -0.4% |
| 2019 | $87.32 | +37.3% |
| 2018 | $63.59 | -32.9% |
| 2017 | $94.71 | -5.5% |
Trading Range
The price is 0.1% above its 50-day average of $118.94 and 9.2% above its 200-day average of $109.10.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $119.09 | |
| 52-week high | $132.60 | -10.2% |
| 52-week low | $89.25 | +33.4% |
| 50-day average | $118.94 | +0.1% |
| 200-day average | $109.10 | +9.2% |
Price Risk
Over 3 years, its largest fall from a peak was 33.8%.
| Measure | Value |
|---|---|
| 1-year beta | 0.45 |
| Largest fall, 1 year | -18.3% |
| Largest fall, 3 years | -33.8% |
Valuation
Incyte traded at 14.5x earnings at the end of 2025, against a 5-year median of 24.9x.
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About INCY
What is INCY's 1-year price change?
Incyte's price rose 14.3% over the past 12 months. With dividends included, the 12-month total return was 14.3%.
What is INCY's 5-year price change?
Incyte's month-end price rose 79.7% over the 5 years through Oct 2026, a compound annual rate of 12.4%. These figures leave out dividends.
What is INCY's 52-week high and low?
Incyte's 52-week high is $132.60 and its 52-week low is $89.25. Its latest price of $119.09 on Nov 17, 2026 is 10.2% below the high.
What is INCY's beta?
Incyte's 1-year beta against the S&P 500 is 0.45, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 18.3%.
Is the INCY chart free?
Yes. Advanced Charting for INCY is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
INCY pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation